Biotage receives an order for multiple cGMP HPLC systems

One of the world’s leading peptide suppliers has purchased multiple Kiloprep® 2000 HPLC systems, cartridge modules and cartridges totaling approximately 8.5 MSEK (1.1 MUSD). These instruments and consumables will be used to purify 100’s of kilograms of a new peptide therapeutic. “This recent investment is the result of a 15-year relationship based upon Biotage’s expertise in prepacked cartridge technology and custom systems engineering” says Jeff Bork, President and CEO of Biotage AB. Biotage builds a variety of large-scale instrumentation for pilot production and cGMP manufacturing. These systems are custom designed to produce kilogram quantities of peptides, oligonucleotides and other products. The Kiloprep® systems and the cartridges provide a turnkey solution ideally suited for validated processes. “Biotage has the unique capability to provide automated synthesis and purification tools that range in scale from milligram to kilogram," says David Patteson, President of Biotage, Discovery Chemistry Group. The KP 2000 instruments and majority of cartridges will be delivered in 2005. Contact: Jeff Bork, President and CEO Tel: +46 734 22 16 60, jeff.bork@biotage.se David Patteson, President of Biotage, Discovery Chemistry Group Tel: +1 434 220 2622, dpatteson@biotage.com About Biotage Biotage is a global company active in life science research with strong technologies, a broad range of operations and a long-term view of the market. The company offers solutions, knowledge and experience in the areas of genetic analysis and medicinal chemistry. Customers include the world’s top 30 pharmaceutical companies, 20 largest biotech companies and leading academic institutes. The company is headquartered in Uppsala and has offices in the US, Japan, UK and several other European countries. Biotage has approx. 340 employees and had pro-forma sales of approx. 500 MSEK in 2004. Biotage is listed on the Stockholm stock exchange. Website: www.biotage.com Certain statements in this press release are forward-looking. These may be identified by the use of forward- looking words or phrases such as "believe," "expect," "intend," and "should," among others. These forward-looking statements are based on Biotage’s current expectations. The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for such forward-looking statements. In order to comply with the terms of the safe harbor, Biotage notes that a variety of factors could cause actual results and experience to differ materially from the anticipated results or other expectations expressed in such forward-looking statements. Such uncertainties and risks include, but are not limited to, risks associated with management of growth and international operations (including the effects of currency fluctuations), variability of operating results, the commercial development of the microwave synthesis and flash purification in the drug discovery market, DNA sequencing and genomics market, nucleic acid-based molecular diagnostics market, and genetic vaccination and gene therapy markets, competition, rapid or unexpected changes in technologies, fluctuations in demand for Biotage’s products (including seasonal fluctuations), difficulties in successfully adapting the Company's products to integrated solutions and producing such products, and the Company's ability to identify and develop new products and to differentiate its products from competitors.